Pharmaceutical News

RSS

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company focused on Consolidating, Re-Branding and Launching "Matured & Orphan Drugs," has announced its most recent product Lomustine (CCNU), formerly known as CeeNu® by Bristol-Myers Squibb (BMS), which has officially been removed from the U.S. Food & Drug Administration (FDA) Drug Shortage List.

27 Jan 2014

Study explores potential of antibody-drug conjugates and challenges in manufacturing them

After years of research, development and testing, a new class of drugs is emerging on the market with two frontrunners acting as harbingers of what's to come. The cover story in Chemical & Engineering News, ACS' weekly newsmagazine, explores the potential of these antibody-drug conjugates (ADCs) and the challenges in developing and manufacturing them.

27 Jan 2014

NIBIO signs collaboration agreement for clinical development of new mucosal TB vaccines

Japan's National Institute of Biomedical Innovation ("NIBIO"), Aeras and Create Vaccine Company, Ltd ("CREATE") announce today that they signed a collaboration agreement on December 26, 2013, on the preclinical and clinical development of new mucosal tuberculosis (TB) vaccines based on NIBIO's human parainfluenza type-2 (rhPIV2) vector technology.

27 Jan 2014

Researchers develop novel compound known to reverse spread of malignant breast cancer cells

Researchers at Cardiff University are developing a novel compound known to reverse the spread of malignant breast cancer cells.

26 Jan 2014

Cantrell Drug Company amends FDA registration to include 503B compounding outsourcing facility

Cantrell Drug Company today announced amendment of its U.S. Food and Drug Administration (FDA) registration to include the new 503B "compounding outsourcing facility" designation established under the recently passed Drug Quality and Security Act so that it can continue to serve patients nationwide with sterile medications that meet the most exacting quality standards.

25 Jan 2014

New drugs for treatment of prostate cancer may not target root cause of the disease

NEW drugs being developed for the treatment of prostate cancer may not be targeting the root cause of the disease, according to research published today (Friday, 24 January 2014) in Cell Death & Differentiation.

25 Jan 2014

Aspirin intake correlates with halted growth of lethal intracranial tumor

Researchers from Massachusetts Eye and Ear, Harvard Medical School, Massachusetts Institute of Technology and Massachusetts General Hospital have demonstrated, for the first time, that aspirin intake correlates with halted growth of vestibular schwannomas (also known as acoustic neuromas), a sometimes lethal intracranial tumor that typically causes hearing loss and tinnitus.

24 Jan 2014

FDA gives final approval to Perrigo's ANDA for repaglinide tablets 1 mg and 2 mg

Perrigo Company plc today announced that it has received final approval from the U.S. Food & Drug Administration for its abbreviated new drug application for repaglinide tablets 1 mg and 2 mg, the generic equivalent to Prandin Tablets (repaglinide tablets) and has commenced shipment of product. Perrigo previously launched the 0.5 mg strength in 2013.

24 Jan 2014

NICE approves MabThera for treating severe forms of GPA and MPA

Today the National Institute for Health and Care Excellence has approved the use of MabThera for two potentially life-threatening auto-immune diseases, GPA and MPA, which result in the inflammation and damage of small blood vessels and frequently involve multiple organs. The two diseases affect over 13,000 people in the UK and are characterised by the breaking down of specific areas of tissue in the body that, if not treated, can lead to organ damage, organ failure and even death.

24 Jan 2014

Study examines existing evidence related to health benefits of vitamin D

A new study concludes that evidence is lacking for substantial health benefits of vitamin D – and that results of several multimillion-dollar trials currently underway are unlikely to alter this view.

24 Jan 2014

Scientists identify molecules that block accumulation of toxic eye protein responsible for early onset of glaucoma

Using a novel high-throughput screening process, scientists have for the first time identified molecules with the potential to block the accumulation of a toxic eye protein that can lead to early onset of glaucoma.

24 Jan 2014

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease, according to scientists at Weill Cornell Medical College who led a multinational research team.

24 Jan 2014

Study suggests potential therapeutic role of aspirin in inhibiting vestibular schwannoma growth

24 Jan 2014

Mylan Pharmaceuticals launches Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg. This product is the generic version of Novo Nordisk's Prandin, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

24 Jan 2014

FDA grants final approval for Hi-Tech Pharmacal's Bromfenac Ophthalmic Solution ANDA

Hi-Tech Pharmacal Co., Inc., a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, granted final approval for the Company's Abbreviated New Drug Application, for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day), the generic for ISTA Pharmaceuticals' Bromday ophthalmic solution, 0.09%.

23 Jan 2014

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia.

23 Jan 2014

Structural biologists advance efforts to develop new drugs targeting NMDA receptors in brain

Structural biologists at Cold Spring Harbor Laboratory (CSHL) and collaborators at Emory University have obtained important scientific results likely to advance efforts to develop new drugs targeting NMDA receptors in the brain.

23 Jan 2014

Anti-malaria drug combination may help prevent pregnancy complications in women with lupus

An anti-malaria drug combination might be useful in helping to prevent pregnancy complications in women with lupus and the related disorder antiphospholipid syndrome, Yale School of Medicine researchers have found in a new study published in the American Journal of Reproductive Immunology.

23 Jan 2014

New drug helps children and young adults who have severe pain from sickle cell disease

Saint Louis University researchers are studying whether ReoPro® (abciximab), a drug currently given to heart patients undergoing angioplasties to open blocked arteries, also could help children and young adults who have severe pain from sickle cell disease.

23 Jan 2014

Rice University scientists create new technique to widen bottleneck for pharmaceutical, other industries

Rice University scientists have created a way to fine tune a process critical to the pharmaceutical industry that could save a lot of time and money.

23 Jan 2014

Pharmaceutical News

NextSource BioTechnology announces product re-launch, market availability of Lomustine in U.S.

Study explores potential of antibody-drug conjugates and challenges in manufacturing them

NIBIO signs collaboration agreement for clinical development of new mucosal TB vaccines

Researchers develop novel compound known to reverse spread of malignant breast cancer cells

Cantrell Drug Company amends FDA registration to include 503B compounding outsourcing facility

New drugs for treatment of prostate cancer may not target root cause of the disease

Aspirin intake correlates with halted growth of lethal intracranial tumor

FDA gives final approval to Perrigo's ANDA for repaglinide tablets 1 mg and 2 mg

NICE approves MabThera for treating severe forms of GPA and MPA

Study examines existing evidence related to health benefits of vitamin D

Scientists identify molecules that block accumulation of toxic eye protein responsible for early onset of glaucoma

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

Study suggests potential therapeutic role of aspirin in inhibiting vestibular schwannoma growth

Mylan Pharmaceuticals launches Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg

FDA grants final approval for Hi-Tech Pharmacal's Bromfenac Ophthalmic Solution ANDA

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

Structural biologists advance efforts to develop new drugs targeting NMDA receptors in brain

Anti-malaria drug combination may help prevent pregnancy complications in women with lupus

New drug helps children and young adults who have severe pain from sickle cell disease

Rice University scientists create new technique to widen bottleneck for pharmaceutical, other industries

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News